Tectonic Therapeutic (TECX) Insider Filing: RSUs and Option Details for CEO
Rhea-AI Filing Summary
Tectonic Therapeutic CEO and director Reicin Alise reported multiple equity awards and holdings on Form 4. The filing shows acquisition on 09/25/2025 of 14,700 restricted stock units (RSUs) that vest in three equal annual installments on 09/25/2026, 09/25/2027 and 09/25/2028, subject to continued service. The reporting person also holds an employee stock option to buy 26,710 shares at $14.71 per share exercisable beginning 09/25/2025 with expiration 09/24/2035; the option vests monthly over 48 installments starting 10/25/2025.
The report discloses 228,185 shares beneficially owned directly after the RSU acquisition and 124,530 shares held indirectly by the Reicin-Boiarsky Family Trust, where the reporting person may share voting and dispositive power but disclaims beneficial ownership except to extent of pecuniary interest.
Positive
- Clear disclosure of equity awards: 14,700 RSUs with explicit vesting dates and a 26,710-share option at $14.71 with defined vesting schedule
- Substantial reported ownership: 228,185 shares beneficially owned following the transaction and 124,530 shares held in a family trust
- Transparent trust disclosure: Filing explains co-trustee relationship and disclaimers regarding beneficial ownership of trust-held shares
Negative
- None.
Insights
TL;DR: CEO received equity awards and holds substantial direct and indirect stock positions, consistent with standard executive compensation.
The Form 4 documents a grant of 14,700 RSUs and an outstanding option for 26,710 shares at a $14.71 exercise price, with explicit vesting schedules. The report also shows 228,185 shares directly beneficially owned after the RSU acquisition and 124,530 shares held by a family trust. These disclosures are routine for an executive and provide clear timing for when additional shares may convert into voting stock under service-based vesting conditions.
TL;DR: Disclosure clarifies direct holdings, option economics, vesting timelines and indirect ownership via family trust.
The filing precisely states the nature of indirect ownership through the Reicin-Boiarsky Family Trust and includes a disclaimer regarding beneficial ownership limited to pecuniary interest. Vesting terms for both RSUs and the option are specified, which aids transparency about future dilution timing and executive retention mechanics. No amendments or corrective statements are indicated.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 26,710 | $0.00 | -- |
| Grant/Award | Common Stock | 14,700 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of September 25, 2026, September 25, 2027 and September 25, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date. These shares are held by the Reicin-Boiarsky Family Trust (the "Trust"). The Reporting Person's spouse is a co-trustee of the Trust. Accordingly, the Reporting Person may be deemed to have shared voting and dispositive power over the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
